Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: A randomized, double-blind, placebo-controlled, patient-initiated clinical trial

Journal of the American Academy of Dermatology

Volumn 64, Issue 4, 2011, Pages 696.e1-696.e11

  Hull, Christopher M ^a,b   Harmenberg, Johan ^b   Arlander, Eva ^c   Aoki, Fred ^d   Bring, Johan ^e   Darpö, Börje ^b,c   Levin, Myron J ^f   Tyring, Stephen ^g   Spruance, Spotswood L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEDIVIR AB   (Sweden)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF GÄVLE   (Sweden)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

episodic treatment; herpes labialis; herpes simplex virus; prevention; recurrence

Indexed keywords

ACICLOVIR; ACICLOVIR PLUS HYDROCORTISONE; ME 609; PLACEBO; UNCLASSIFIED DRUG; XERCLEAR; XERESE;

ADULT; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; ARTICLE; CHAPPED LIPS; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; HERPES LABIALIS; HERPES SIMPLEX VIRUS; HUMAN; LIP DISEASE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINOPHARYNGITIS; SORE THROAT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS CULTURE;

EID: 79952815731     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.08.012     Document Type: Article

References (22)

1. Spruance SL. The natural history of recurrent oral-facial herpes simplex virus infection. Semin Dermatol 1992;11:200-6.
2. Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J Infect Dis 2000;181:1906-10. (Pubitemid 30416151)
3. Hull C, McKeough M, Sebastian K, Kriesel J, Spruance S. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol 2009;23:263-7.
4. Spruance SL, Schnipper LE, Overall JC Jr, Kern ER, Wester B, Modlin J, et al. Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis 1982;146:85-90. (Pubitemid 12045340)
5. Spruance SL, Crumpacker CS, Schnipper LE, Kern ER, Marlow S, Arndt KA, et al. Early, patient-initiated treatment of herpes labialis with topical l0% acyclovir. Antimicrob Agents Chemother 1984;25:553-5. (Pubitemid 14101138)
6. Raborn GW, McGaw WT, Grace M, Percy J, Samuels S. Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind, randomized trial. Oral Surg Oral Med Oral Pathol 1989;67:676-9. (Pubitemid 19163761)
7. Spruance SL. Treatment of herpes simplex labialis. In: De Clerq E, editor. Clinical use of antiviral drugs. Boston (MA): Martinus Nijhoff; 1988. pp. 67-86.
8. Spruance SL. Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD, editors. Clinical management of herpes viruses. Amsterdam: IOS Press; 1995. pp. 3-42.
9. Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes 2002;9:64-9. (Pubitemid 37486598)
10. Spruance SL, Evans TG, McKeough MB, Thai L, Araneo BA, Daynes RA, et al. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res 1995;28:39-55.
11. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002;46:1870-4. (Pubitemid 34535209)
12. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial; topical penciclovir collaborative study group. JAMA 1997;277:1374-9. (Pubitemid 27194948)
13. Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47:1072-80. (Pubitemid 36254237)
14. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions. J Clin Invest 1985;75:226-33.
15. Cunningham AL, Noble JR. Role of keratinocytes in human recurrent herpetic lesions. J Clin Invest 1989;83:490-6.
16. Hull CM, McKenna JK, Zone JJ. Topical corticosteroids and bullous pemphigoid. Arch Dermatol 2003;139:225-6.
17. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002;46:2238-43. (Pubitemid 34665922)
18. Spruance SL, Stewart JCB, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90. (Pubitemid 20056644)
19. Harmenberg JG, Awan AR, Alenius S, Stahle L, Erlandsson AC, Lekare G, et al. ME-609: a treatment for recurrent herpes simplex virus infections. Antivir Chem Chemother 2003;14:205-15. (Pubitemid 37267735)
20. Brinkmann I, Muller-Goymann CC. An attempt to clarify the influence of glycerol, propylene glycol, isopropyl myristate and a combination of propylene glycol and isopropyl myristate on human stratum corneum. Pharmazie 2005;60:215-20. (Pubitemid 40461354)
21. Kern ER, Glasgow LA, Overall JC Jr, Reno JM, Boezi JA. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate. Antimicrob Agents Chemother 1978;14:817-23. (Pubitemid 9074627)
22. Spruance SL, Hill J. Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valacyclovir trials. J Antimicrob Chemother 2004;53:703-7. (Pubitemid 38660269)